Quarterly report · Q3
4572.TEDINET S100S238
Period2023-01-01 → 2023-09-30
Filed2023-11-08
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥711m | 2023-01-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥1.4bn | 2022-01-01 → 2022-12-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.1bn | 2022-01-01 → 2022-09-30 | Cons. | Net sales |
| Operating income | −¥1.2bn | 2023-01-01 → 2023-09-30 | Cons. | Operating income |
| Operating income | −¥754m | 2022-01-01 → 2022-09-30 | Cons. | Operating income |
| Ordinary income | −¥1.2bn | 2023-01-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | −¥1.3bn | 2022-01-01 → 2022-12-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥736m | 2022-01-01 → 2022-09-30 | Cons. | Ordinary income |
| Profit before tax | −¥1.2bn | 2023-01-01 → 2023-09-30 | Cons. | Income before income taxes |
| Profit before tax | −¥779m | 2022-01-01 → 2022-09-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥1.2bn | 2023-01-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥1.3bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥795m | 2022-01-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥1.2bn | 2023-01-01 → 2023-09-30 | Cons. | Profit loss |
| Net income | −¥795m | 2022-01-01 → 2022-09-30 | Cons. | Profit loss |
| Total assets | ¥4.2bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥4.3bn | at 2022-12-31 | Cons. | Assets |
| Total assets | ¥4.5bn | at 2022-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥376m | at 2023-09-30 | Cons. | Liabilities |
| Total liabilities | ¥625m | at 2022-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥3.8bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥3.6bn | at 2022-12-31 | Cons. | Net assets |
| Net assets / equity | ¥3.9bn | at 2022-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥3.4bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥3.4bn | at 2022-12-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥-73.74 | 2023-01-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-20.13 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-99.1 | 2022-01-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-58.56 | 2022-01-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-31.92 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 91.0% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 85.0% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 86.5% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 10
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q3r_E00987-000Drug Discovery Businessreportable segment | segment profit | 2023-01-01 → 2023-09-30 | −¥1.4bn |
| jpcrp040300-q3r_E00987-000Drug Discovery Support Businessreportable segment | revenue | 2023-01-01 → 2023-09-30 | ¥711m |
| jpcrp040300-q3r_E00987-000Drug Discovery Support Businessreportable segment | revenue external | 2023-01-01 → 2023-09-30 | ¥711m |
| jpcrp040300-q3r_E00987-000Drug Discovery Support Businessreportable segment | segment profit | 2023-01-01 → 2023-09-30 | ¥218m |
| jpcrp040300-q3r_E00987-000Drug Discovery Businessreportable segment | revenue | 2022-01-01 → 2022-09-30 | ¥286m |
| jpcrp040300-q3r_E00987-000Drug Discovery Businessreportable segment | revenue external | 2022-01-01 → 2022-09-30 | ¥286m |
| jpcrp040300-q3r_E00987-000Drug Discovery Businessreportable segment | segment profit | 2022-01-01 → 2022-09-30 | −¥1.1bn |
| jpcrp040300-q3r_E00987-000Drug Discovery Support Businessreportable segment | revenue | 2022-01-01 → 2022-09-30 | ¥810m |
| jpcrp040300-q3r_E00987-000Drug Discovery Support Businessreportable segment | revenue external | 2022-01-01 → 2022-09-30 | ¥810m |
| jpcrp040300-q3r_E00987-000Drug Discovery Support Businessreportable segment | segment profit | 2022-01-01 → 2022-09-30 | ¥336m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 306
| Item | Context | Value | Unit |
|---|---|---|---|
| Net sales | Prior1YTDDuration_jpcrp040300-q3r_E00987-000DrugDiscoverySupportBusinessReportableSegmentsMember | 809562000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q3r_E00987-000DrugDiscoveryBusinessReportableSegmentsMember | 286045000 | JPY |
| Net sales | Prior1YTDDuration | 1095607000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q3r_E00987-000DrugDiscoverySupportBusinessReportableSegmentsMember | 335507000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q3r_E00987-000DrugDiscoveryBusinessReportableSegmentsMember | -1089213000 | JPY |
| Operating income | Prior1YTDDuration | -753705000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E00987-000DrugDiscoverySupportBusinessReportableSegmentsMember | 711294000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E00987-000DrugDiscoveryBusinessReportableSegmentsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 711294000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E00987-000DrugDiscoverySupportBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E00987-000DrugDiscoveryBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E00987-000DrugDiscoverySupportBusinessReportableSegmentsMember | 711294000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E00987-000DrugDiscoveryBusinessReportableSegmentsMember | － | JPY |
| Net sales | CurrentYTDDuration | 711294000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E00987-000DrugDiscoverySupportBusinessReportableSegmentsMember | 218480000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E00987-000DrugDiscoveryBusinessReportableSegmentsMember | -1420236000 | JPY |
| Operating income | CurrentYTDDuration | -1201755000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の4の7第1項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)近畿財務局長 | |
| Filing date cover page | FilingDateInstant | 2023-11-08 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第21期第3四半期(自 2023年7月1日 至 2023年9月30日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)カルナバイオサイエンス株式会社 | |
| Company name in english cover page | FilingDateInstant | Carna Biosciences, Inc. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 吉野公一郎 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)神戸市中央区港島南町一丁目5番5号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)078-302-7039（代表） | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)取締役経営管理本部長 山本詠美 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)神戸市中央区港島南町一丁目5番5号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)078-302-7039（代表） | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)取締役経営管理本部長 山本詠美 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E00987 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 45720 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)カルナバイオサイエンス株式会社 | |
| Filer name in english | FilingDateInstant | Carna Biosciences, Inc. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | cte | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2023-01-01 | |
| Current period end date | FilingDateInstant | 2023-09-30 | |
| Type of current period | FilingDateInstant | Q3 | |
| Current fiscal year end date | FilingDateInstant | 2023-12-31 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |